Precision Medicine and Antigens – The Case of HLA and GADSpecific Immunotherapy in Type 1 Diabetes

Time: 4:00 pm
day: Day One


  • Retrospective and prospective clinical data show that individuals carrying HLA variants associated with autoimmunity against GAD (glutamic acid decarboxylase) respond to GAD-specific immunotherapy, supporting the notion of precision medicine in Type 1 Diabetes
  • By prescreening for the presence of HLA DR3-DQ2, the HLA haplotype associated with GAD-specific autoimmunity, individuals that have a high likelihood of responding to GAD-specific immunotherapy can be selected for clinical trials
  • The importance of HLA for immunity and antigen presentation provides a rational platform to develop antigen-specific therapies for heterogeneous diseases